---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-277639"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2026-06-22T20:53:52+00:00"
generated_at: "2026-06-22T20:55:15.399530+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Atea stockholders reelect all three Class III directors; KPMG ratified; say-on-pay passes

## Summary
- Jerome Adams, Howard Berman, Barbara Duncan elected as Class III directors (for votes: 28.8M, 44.5M, 43.7M).
- Ratification of KPMG as auditor for FY2026: 58.9M for, 0.78M against, 65.5K abstain.
- Advisory approval of exec compensation: 47.5M for, 3.0M against, 643.6K abstain; broker non-vote 8.7M.
- Approximately 74.65% of outstanding shares represented at the meeting (59.7M shares).

## SEC filing metadata
- accession: 0001193125-26-277639
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2026-06-22T20:53:52+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312526277639/0001193125-26-277639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312526277639/d11075d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-277639
- JSON: https://secwatch.observer/filing/0001193125-26-277639.json
- Plain text: https://secwatch.observer/filing/0001193125-26-277639.txt

## Key facts
- Shareholder Votes
  Atea Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-18 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-18
  source text: Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. FOR AGAINST ABSTAIN BROKER NON-VOTE 58,894,207 783,081 65,531 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312526277639/0001193125-26-277639-index.htm
- Shareholder Votes
  Atea Pharmaceuticals, Inc. shareholders approved Election of three Class III Directors to serve until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. at the 2026-06-18 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-18
  source text: Proposal 1 — Election of three Class III Directors to serve until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. FOR WITHHOLD BROKER NON-VOTE Jerome Adams, MD, MPH 28,798,012 22,275,665 8,669,142 Howard Berman, PhD 44,466,627 6,607,050 8,669,142 Barbara Duncan 43,697,098 7,376,579 8,669,142
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312526277639/0001193125-26-277639-index.htm
- Shareholder Votes
  Atea Pharmaceuticals, Inc. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. at the 2026-06-18 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-18
  source text: Proposal 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 47,452,759 2,977,290 643,628 8,669,142
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312526277639/0001193125-26-277639-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.